Новые железосодержащие фосфат-связывающие препараты в коррекции гиперфосфатемии у больных хронической болезнью почек


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В обзоре суммированы сведения о новых железосодержащих фосфат-связывающих препаратах, которые по эффективности и безопасности не уступают другим фосфатбиндерам. Использование оксигидроксида железа (Velphoro) снижает уровень фосфора в сыворотке, существенно уменьшает лекарственную нагрузку, улучшая комплаентность больных к проводимой терапии и ее результаты, а железа цитрат повышает запасы железа в организме, снижая затраты на лечение анемии у больных ХБП.

Полный текст

Доступ закрыт

Об авторах

В. М Ермоленко

ФГБОУ ДПО РМАПО Минздрава России

д.м.н., профессор, зав. кафедрой нефрологии и гемодиализа

Н. Н Филатова

ФГБОУ ДПО РМАПО Минздрава России

Email: nephrology@mail.ru
к.м.н., доцент кафедры нефрологии и гемодиализа

Список литературы

  1. O’Seaghdha C.M., Hwang S.J., Muntner P. et al. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2011; 26(9): 2885-2890.
  2. Zoccali C., Ruggenenti P., Perna A. et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011; 22(10): 1923-1930.
  3. Giacelli C. The emerging role of phosphate in vascular calcification. Kidney Int. 2009; 75(9): 890-897.
  4. Eddington H., Hoefield R., Sinha S. et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5(12): 2251-2257.
  5. Kestenbaum B., Sampron J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16(2): 520-528.
  6. Dhingra R., Sullivan L.M., Fox C.S. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167(9): 879-885.
  7. Isakova T., Wahl P., Vargas G.S. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12): 1370-1378.
  8. Locatelli F., Del Vecchio L. Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother. 2014; 15(3): 307-309.
  9. Block C.A., Wheeler D.C., Persky M.S. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23(8): 1407-1415.
  10. Geisser P., Philipp E. Adsorbens für Phosphat aus wässrigem Medium, dessen herstellung und verwendung. German Pat Appl. 1995; DE 195 47 356 A1.
  11. Hergesell O., Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999; 14(4): 863-867.
  12. Geisser P., Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010; 74(1): 4-11.
  13. Wüthrich R., Chonchol M., Covic A. et al. Randomized clinical trial ofthe iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013; 8(2): 280-289.
  14. Floege J., Covic A., Ketteler M. et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014; 86(3): 638-647.
  15. Covic A., Floege J., Ketteler M. et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2016 Jun 23; pii: gfw242.
  16. Daugirdas JT, Finn WF, Emmett M, Chertow GM. Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Semin Dial. 2011; 24(1): 41-49.
  17. Ficociello L., Ma L., Parameswaran V. et al. Real-world use of sucroferric oxyhydroxide and hemodialysis patients: Changes in the serum phosphorus control and phosphate binder pill burden. 2015; Poster presented at American Society of Nephrology Annual Meeting 2015. Abstract 37.
  18. Battistella M., Fleites R., Wong R., Jassal S.V. Development, validation, and implementation of a medication adherence survey to seek a better understanding of the hemodialysis patient. Clin Nephrol. 2016; 85(1):12-22.
  19. Yang W., Yang C., Hou C. et al. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002; 17(2): 265-270.
  20. Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel). 2014; 7(10): 990-998.
  21. Sinsakul M., Sika M., Koury M. et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012; 121(1-2): c25-29.
  22. Dwyer J., Sika M., Schulman G. et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013; 61(5): 759-766.
  23. Yokoyama K., Hirakata H., Akiba T. et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014; 9(3): 543-552.
  24. Lewis J., Sika M., Koury M. et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015; 26(2): 493-503.
  25. Mutell R., Rubin J.L., Bond T.C., Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013; 6: 79-87.
  26. Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis. 2014; 7: 191-201.
  27. Iida A., Kemmochi Y., Kakimoto K. et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013; 37(4): 346-358.
  28. Phan O., maillard M., Peregaux C. et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013; 346(2): 281-289.
  29. Deger S.M., Erten Y., Pasaoglu O.T. et al. The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol. 2013; 17(3): 416-423.
  30. Block G.A., Fishbane S., Rodriguez M. et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis. 2015; 65(5): 728-736.
  31. Cernaro V., Santoro D., Lucisano S. et al. The future of phosphate binders: a perspective on novel therapeutics. Expert Opin Investig Drugs. 2014; 23(11): 1459-1463.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать